Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, said the American Journal of Pharmacy Benefits published results from a real-world analysis comparing health care resource utilization data among nearly 4,000 recently diagnosed nonvalvular atrial fibrillation patients newly treated with direct thrombin inhibitor Pradaxa (dabigatran etexilate mesylate) or warfarin.